Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

1.1.1.62: 17beta-estradiol 17-dehydrogenase

This is an abbreviated version!
For detailed information about 17beta-estradiol 17-dehydrogenase, go to the full flat file.

Word Map on EC 1.1.1.62

Reaction

17beta-estradiol
+
NAD(P)+
=
estrone
 +
NAD(P)H
 +
H+

Synonyms

(17beta-HSD) type 1, (17beta-HSD) type 2, 17-beta-HSD 2, 17-beta-hydroxysteroid dehydrogenase type 12, 17-beta-hydroxysteroid dehydrogenase type 2, 17-HOR, 17-HSD, 17beta HSD1, 17beta,20alpha-hydroxysteroid dehydrogenase, 17beta-estradiol dehydrogenase, 17beta-HSD, 17beta-hsd 14, 17beta-HSD I, 17beta-HSD type 1, 17beta-HSD type 12, 17beta-HSD type 2, 17beta-HSD type 4, 17beta-HSD type 5, 17beta-HSD type 7, 17beta-HSD type 8, 17beta-HSD1, 17beta-HSD10, 17beta-HSD12, 17beta-HSD14, 17beta-HSD2, 17beta-HSD4, 17beta-HSD5, 17beta-HSD7, 17beta-HSD7 2, 17beta-HSDcl, 17beta-hydroxysteroid dehydrogenase, 17beta-hydroxysteroid dehydrogenase 1, 17beta-hydroxysteroid dehydrogenase 2, 17beta-hydroxysteroid dehydrogenase 4, 17beta-hydroxysteroid dehydrogenase type 1, 17beta-hydroxysteroid dehydrogenase type 10, 17beta-hydroxysteroid dehydrogenase type 12, 17beta-hydroxysteroid dehydrogenase type 14, 17beta-hydroxysteroid dehydrogenase type 2, 17beta-hydroxysteroid dehydrogenase type 4, 17beta-hydroxysteroid dehydrogenase type 5, 17beta-hydroxysteroid dehydrogenase type 6, 17beta-hydroxysteroid dehydrogenase type 7, 17beta-hydroxysteroid dehydrogenase type 8, 17beta-hydroxysteroid dehydrogenase type I, 17beta-hydroxysteroid dehydrogenase type IV, 17beta-hydroxysteroid dehydrogenase types 1, 17beta-hydroxysteroid dehydrogenases type 1, 17betaHSD, 17betaHSD1, 17betaHSD14, 17betaHSD6, 17HSD1, 20 alpha-hydroxysteroid dehydrogenase, 20-alpha-HSD, 20alpha-hydroxysteroid dehydrogenase, 3beta-HSD, 3beta-hydroxysteroid dehydrogenase, 3betaHSD, 7beta-HSD type 1, 7beta-HSD7, AKR1B15, AKR1C1, AKR1C2, AKR1C3, AKR1C4, aldo-keto reductase 1B15, C6Y55_RS00895, C6Y55_RS01070, C6Y55_RS01190, C6Y55_RS15130, dehydrogenase, estradiol 17beta-, E2DH, EDH, estradiol 17beta-dehydrogenase, estradiol dehydrogenase, estrogen 17-oxidoreductase, estrogenic 17beta-hydroxysteroid dehydrogenase, form 2 type 7 17beta-hydroxysteroid dehydrogenase, HSD17B1, HSD17B12, HSD17B2, HSD17B4, HSD17B7, hydroxysteroid (17-beta) dehydrogenase 1, Ke6 protein, mf17beta-HSD12, microsomal 17-beta-hydroxysteroid dehydrogenase, More, NlHsd17b12, oestradiol-17beta hydroxysteroid dehydrogenase, placental 17-beta-hydroxysteroid dehydrogenase, PRAP, PRL receptor associated protein, reductive 17beta-hydroxysteroid dehydrogenase type 7, testicular 17-beta-hydroxysteroid dehydrogenase, type 1 17beta-HSD, type 1 17beta-hydroxysteroid dehydrogenase, type 12 17beta-HSD, type 12 17beta-hydroxysteroid dehydrogenase, type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase, type 5 17-hydroxysteroid dehydrogenase/prostaglandin F synthase, type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase, type 7 17beta-hydroxysteroid dehydrogenase, type 8 17beta-HSD, type 8 17beta-hydroxysteroid dehydrogenase

ECTree

     1 Oxidoreductases
         1.1 Acting on the CH-OH group of donors
             1.1.1 With NAD+ or NADP+ as acceptor
                1.1.1.62 17beta-estradiol 17-dehydrogenase

Expression

Expression on EC 1.1.1.62 - 17beta-estradiol 17-dehydrogenase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
17beta-estradiol treatments increase HSD17B4 mRNA in the auditory region of males, which is contraryto findings in the song system
application of medroxyprogestrone acetate, dydrogesterone and dienogest significantly decreases isoforms HSD17B1 and CYP19A1 expression and significantly increases isoform HSD17B2 expression. Dydrogesterone and dienogest also significantly suppress estrogen receptors ESR1 and ESR2 transcription, whereas medroxyprogestrone acetate and dydrogesterone significantly reduce mRNA levels of G protein-coupled estrogen receptor 1. Results thus suggest that in peritoneal endometriosis the beneficial effects of these progestins can be explained by lower HSD17B1 and higher HSD17B2 mRNA and protein levels, which lead to reduced local estradiol biosynthesis
aromatase inhibitor treatment results in 17betaHSD1 upregulation in both A-549 and LK-87 cells
CrgA activates the expression of 17beta-hsd through its binding to the motif of T-N11-A
dihydrotestosterone treatment increases HSD17B2 expression, with limited effect on HSD17B1 expression
downregulation of CX3CL1, EPHB6, and TP63 increases HSD17B1 and HSD17B2 expression
elevated levels of 17beta-estradiol occur in male patients with chronic lymphocytic leukemia
endometrial 17beta-hydroxysteroid dehydrogenase activity is decreased on days 15-16 in pregnant and cyclic pigs compared with the preceding days
exposure to tributyltin chloride at 100 ng Sn2+/l causes a decrease in mRNA levels in digestive gland, after one and two months, while no effect is observed in gonads
expression is relatively low in most tissues and high in prostate and mammary glands in regulating androgen and estrogen levels. In many cancers, overexpression of AKR1C3 is observed
expression of HSD17B2 is increased in ERalpha-negative breast cancer
GREB1 downregulation promotes HSD17B2 expression
higher expression of 17beta-HSD1 mRNA is demonstrated in almost 50% of breast cancer tissues. Expression and activity of 17beta-HSD1 are significantly higher in breast cancer than in normal breast tissue
-
HSD17B1 expression is increased in breast cancer compared with unchanged tissue
HSD17B2 expression is reduced in breast cancer compared with benign tumors
HSD17B2 expression is significantly higher in invasive lobular carcinoma (ILC) than in invasive ductal carcinoma
HSD17B4 mRNA expression levels are higher in males compared to females
-
in non-small cell lung cancer (NSCLC) the expression of HSD17B1 is increased as compared with healthy tissue
induced by 17beta-estradiol
induced by estradiol
miRNA-204-5p, 498, 205-3p and 579-3p reduce HSD17B2 expression
OxyR represses the expression of 17beta-hsd by its specific binding to the conserved motif of GATA-N9-TATC
significant increment of 17beta HSD1 immunoreactivity is found in breast cancer patients treated with aromatase inhibitor exemestane
-